Daiichi Sankyo
Japanese pharmaceutical giant leading in antibody-drug conjugates (ADCs)
公司概况
Daiichi Sankyo is one of Japan's largest pharmaceutical companies and a global leader in antibody-drug conjugate (ADC) technology. The company's partnership with AstraZeneca on Enhertu has produced one of the most successful cancer drugs in recent history. Daiichi Sankyo's ADC pipeline represents a new paradigm in targeted cancer therapy.
为什么关注这家公司
Daiichi Sankyo's ADC platform has established Japan as a global leader in next-generation cancer therapeutics, with a pipeline valued at tens of billions of dollars.
核心关注领域
同行业公司
BeiGene
China's largest global biotech company focused on innovative oncology medicines
Biocon
India's largest biopharmaceutical company and global biosimilars leader
Celltrion
South Korea's leading biosimilar manufacturer challenging global pharma giants
Doctor Anywhere
Southeast Asia's leading omnichannel healthcare platform
Halodoc
Indonesia's leading telehealth and health-tech platform
Healius
Australia's second-largest private pathology and imaging provider
信号时间线
0 条该公司暂无追踪信号。
信号将随官方公告被索引后出现在此处。
我们正在追踪该公司的官方渠道，信号将在发现后自动入库。
当该公司有新信号时，立即收到通知。